Media stories about Trevena (NASDAQ:TRVN) have trended somewhat positive on Friday, AlphaOne reports. The research group, a division of Accern, identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Trevena earned a media sentiment score of 0.16 on AlphaOne’s scale. AlphaOne also gave news articles about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the company’s share price in the near term.

These are some of the news articles that may have impacted AlphaOne Sentiment Analysis’s analysis:

Shares of Trevena (NASDAQ:TRVN) traded down 2.08% during trading on Friday, reaching $3.29. 456,155 shares of the company were exchanged. Trevena has a one year low of $3.23 and a one year high of $8.38. The stock has a 50-day moving average price of $3.59 and a 200-day moving average price of $5.37. The stock’s market capitalization is $187.95 million.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings results on Wednesday, March 8th. The biopharmaceutical company reported ($0.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by $0.05. Trevena had a negative return on equity of 66.50% and a negative net margin of 841.00%. During the same quarter in the prior year, the business earned ($0.30) earnings per share. Analysts forecast that Trevena will post ($1.72) EPS for the current year.

A number of analysts have weighed in on TRVN shares. Zacks Investment Research lowered shares of Trevena from a “hold” rating to a “sell” rating in a research report on Tuesday, March 14th. Cowen and Company restated a “buy” rating and issued a $13.00 target price on shares of Trevena in a research report on Wednesday, March 22nd. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Trevena in a research report on Wednesday, March 22nd. Ladenburg Thalmann Financial Services started coverage on shares of Trevena in a research report on Thursday, February 2nd. They issued a “buy” rating and a $15.00 target price on the stock. Finally, Aegis restated a “positive” rating and issued a $14.00 target price on shares of Trevena in a research report on Wednesday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $11.73.

ILLEGAL ACTIVITY WARNING: This report was first reported by Financial Market News and is the sole property of of Financial Market News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at

About Trevena

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

5 Day Chart for NASDAQ:TRVN

Receive News & Ratings for Trevena Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc and related companies with's FREE daily email newsletter.